Efficient gene transduction in pigs and macaques with the engineered AAV vector AAV.GT5 for hemophilia B gene therapy

Kashiwakura, Y. Endo, K. Ugajin, A. Kikuchi, T. Hishikawa, S. Nakamura, H. Katakai, Y. Baatartsogt, N. Hiramoto, T. Hayakawa, M. Kamoshita, N. Yamazaki, S. Kume, A. Mori, H. Sata, N. Sakata, Y. Muramatsu, S. I. Ohmori, T.
Mol Ther Methods Clin Dev. 2023 Aug 22;30:502-514. doi: 10.1016/j.omtm.2023.08.016.

2023年9月26日(火)からグランシップ(静岡県コンベンションアーツセンター)で開催されます、
日本薬物動態学会第38回年会／第23回シトクロムP450国際会議国際合同大会にて、
弊社より口演発表及び企業展示がございますのでご案内申し上げます。

また、9月25日(月)に同会場で開催の日本薬物動態学会 第16回ショートコースにて、
ランチョンセミナーを開催致しますので、重ねてご案内申し上げます。

Evaluation of RNAi Therapeutics VIR-2218 and ALN-HBV for Chronic Hepatitis B: Results From Randomized Clinical Trials

Gane, E. Lim, Y. S. Kim, J. B. Jadhav, V. Shen, L. Bakardjiev, A. I. Huang, S. A. Cathcart, A. L. Lempp, F. A. Janas, M. M. Cloutier, D. J. Kaittanis, C. Sepp-Lorenzino, L, Hinkle, G. Taubel, J. Haslett, P. Milstein, S. Anglero-Rodriguez, Y. I. Hebner, C. M. Pang, P. S. Yuen, M. F.
J Hepatol. 2023 Jun 6:S0168-8278(23)00352-5. doi: 10.1016/j.jhep.2023.05.023.

Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response

Chida, T. Ishida, Y. Morioka, S. Sugahara, G. Han, C. Lam, B. Yamasaki, C. Sugahara, R. Li, M. Tanaka, Y. Liang, T. J. Tateno, C. Saito, T.
JCI Insight. 2023 May 8;8(9):e162404. doi: 10.1172/jci.insight.162404.

Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection

Burdette, D. Hyrina, A. Song, Z. Beran, R. K. Cheung, T. Gilmore, S. Kobayashi, T. Li, L. Liu, Y. Niedziela-Majka, A. Medley, J. Mehra, U. Morganelli, P. Novikov, N. Niu, C. Tam, D. Tang, J. Wang, J. Yue, Q. Fletcher, S. P. Holdorf, M. M. Delaney, W. E. th Feierbach, B. Lazerwith, S.
Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0134822. doi: 10.1128/aac.01348-22.

Novel AAV-mediated genome editing therapy improves health and survival in a mouse model of methylmalonic acidemia

Zhang, S. Bastille, A. Gordo, S. Ramesh, N. Vora, J. McCarthy, E.Zhang, X. Frank, D. Ko, C. W. Wu, C. Walsh, N. Amarwani, S. Liao, J. Xiong, Q. Drouin, L. Hebben, M. Chiang, K. Chau, B. N.
PLoS One. 2022 Sep 20;17(9):e0274774. doi: 10.1371/journal.pone.0274774.

Novel approach for verification of a human PBPK modeling strategy using chimeric mice in the health risk assessment of epyrifenacil

Hirasawa, K. Abe, J. Nagahori, H. Kitamoto, S
Toxicol Appl Pharmacol. 2023 Apr 15;465:116439. doi: 10.1016/j.taap.2023.116439. Epub 2023 Feb 27.

A Novel Anti-HBV Agent, E-CFCP, restores Hepatitis B virus (HBV)-induced Senescence-associated Cellular Markers Perturbation in Human Hepatocytes

Takamatsu, Y. Hayashi, S. Kumamoto, H. Imoto, S. Tanaka, Y. Mitsuya, H. Higashi-Kuwata, N.
Virus Res. 2023 Mar 23;329:199094. doi: 10.1016/j.virusres.2023.199094.

HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice

Uchida, T. Imamura, M. Hayes, C. N. Suehiro, Y. Teraoka, Y. Ohya, K. Aikata, H. Abe-Chayama, H. Ishida, Y. Tateno, C. Hara, Y. Hino, K. Okamoto, T. Matsuura, Y. Aizaki, H. Wake, K. Kohara, M. Liang, T. J. Oka, S. Chayama, K.
Hepatology. 2023 Mar 13. doi: 10.1097/HEP.0000000000000335.

Identification of SARS-CoV-2 M(pro) inhibitors containing P1′ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2

Higashi-Kuwata, N. Tsuji, K. Hayashi, H. Bulut, H. Kiso, M. Imai, M. Ogata-Aoki, H. .Ishii, T. Kobayakawa, T. Nakano, K. Takamune, N. Kishimoto, N. Hattori, S. I. Das, D. Uemura, Y. Shimizu, Y. Aoki, M. Hasegawa, K. Suzuki, S. Nishiyama, A. Saruwatari, J. Shimizu, Y. Sukenaga, Y. Takamatsu, Y. Tsuchiya, K. Maeda, K. Yoshimura, K. Iida, S. Ozono, S. Suzuki, T. Okamura, T. Misumi, S. Kawaoka, Y. Tamamura, H. Mitsuya, H.
Nat Commun. 2023 Feb 25;14(1):1076. doi: 10.1038/s41467-023-36729-0.

Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants

Yokokawa, H. Shinohara, M. Teraoka, Y. Imamura, M. Nakamura, N. Watanabe, N. Date, T. Aizaki, H. Iwamura, T. Narumi, H. Chayama, K. Wakita, T.
PLoS One. 2022 Sep 22;17(9):e0274283. doi: 10.1371/journal.pone.0274283. eCollection 2022.

Prediction of the human pharmacokinetics of epyrifenacil and its major metabolite, S-3100-CA, by a physiologically based pharmacokinetic modeling using chimeric mice with humanized liver

Hirasawa, K. Abe, J. Nagahori, H. Kitamoto, S.
Toxicol Appl Pharmacol. 2022 Mar 15;439:115912. doi: 10.1016/j.taap.2022.115912.

Discovery of a first-in-class orally available HBV cccDNA inhibitor

Wang, L. Zhu, Q. Zhang, J. D. Zhang, Y. Ni, X. Xiang, K. Jiang, J. Li, B. Yu, Y. Hu, H. Zhang, M. Wu, W. Zeng, J. Yan, Z. Dai, J. Sun, K. Zhang, X. Chen, D. Feng, S. Sach Peltason, L. Young, J. A. T. Gao, L.
J Hepatol. 2022 Dec 29:S0168-8278(22)03466-3. doi: 10.1016/j.jhep.2022.12.014.

Characterization and Prevention of Hypovitaminosis C in Chimeric Mice with Humanized Livers

Touchette, Erin K. Bates, Maria C. Johnson, Mitch C. O’Brien, Tracy C. Melton, Roger J. Long, Kelly R. Kakuni, Masakazu, Baginski, Matthew, Radiloff, Daniel R. Sagartz, John E.
Comparative Medicine 2022, 72(6): 355-363.

Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus

Gilmore, S. A. Tam, D. Cheung, T. L. Snyder, C. Farand, J. Dick, R.Matles, M. Feng, J. Y.Ramirez, R.Li, L. Yu, H. Xu, Y.Barnes, D. Czerwieniec, G. Brendza, K. M. Appleby, T. C. Birkus, G. Willkom, M. Kobayashi, T. Paoli, E. Labelle, M. Boesen, T.Tay, C. H. Delaney, W. E. thNotte, G. T. Schmitz, U. Feierbach, B.
PLoS One. 2022 Dec 7;17(12):e0271145. doi: 10.1371/journal.pone.0271145. eCollection 2022.

Physiologically based pharmacokinetic modeling for quantitative prediction of exposure to a human disproportionate metabolite of the selective Na(v)1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase, using chimeric mice with humanized liver

Asano, D. Nakamura, K. Nishiya, Y. Shiozawa, H. Takakusa, H. Shibayama, T. Inoue, S. I. Shinozuka, T. Hamada, T. Yahara, C. Watanabe, N. Yoshinari, K.
Drug Metab Dispos. 2023 Jan;51(1):67-80. doi: 10.1124/dmd.122.001000. Epub 2022 Oct 23.

Designing receptor agonists with enhanced pharmacokinetics by grafting macrocyclic peptides into fragment crystallizable regions

Sakai, K. Sugano-Nakamura, N. Mihara, E. Rojas-Chaverra, N. M. Watanabe, S. Sato, H. Imamura, R. Voon, D. C. Sakai, I. Yamasaki, C. Tateno, C. Shibata, M. Suga, H. Takagi, J. Matsumoto, K.
Nat Biomed Eng. 2022 Nov 7. doi: 10.1038/s41551-022-00955-6.

Evaluation of the mode of action and human relevance of liver tumors in male mice treated with epyrifenacil

Fukunaga, S. Ogata, K. Eguchi, A. Matsunaga, K. Sakurai, K. Abe, J. Cohen, S. M. Asano, H.
Regul Toxicol Pharmacol. 2022 Oct 6;136:105268. doi: 10.1016/j.yrtph.2022.105268.

Letrozole ameliorates liver fibrosis through the inhibition of the CTGF pathway and 17β-hydroxysteroid dehydrogenase 13 expression

Sakai, N. Kamimura, K. Miyamoto, H. Ko, M. Nagoya, T. Setsu, T. Sakamaki, A. Yokoo, T. Kamimura, H. Soki, H. Tokunaga, A. Inamine, T. Nakashima, M. Enomoto, H. Kousaka, K. Tachiki, H.
J Gastroenterol. 2022 Oct 27. doi: 10.1007/s00535-022-01929-w.

Targeting lipid biosynthesis pathways for hepatitis B virus cure

Hyrina, A. Burdette, D. Song, Z. Ramirez, R. Okesli-Armlovich, A. Vijayakumar, A. Bates, J. Trevaskis, J. L. Fletcher, S. P. Lee, W. A. Holdorf, M. M.
PLoS One. 2022 Aug 4;17(8):e0270273. doi: 10.1371/journal.pone.0270273. eCollection 2022.